Our immunotherapy, currently in clinical trials, works to boost the ability of the body's own cancer fighting cells to search and destroy cancerous tumors.

Bria-IMT™ and Bria-OTS™ are two promising drugs under development in our fight against breast cancer.
Bria-IMT™ has shown remarkable results thus far in clinical trials.

Learn More
BriaCell’s Patented Immunotherapy

Bria-IMT™

Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer fighting cells to attack and destroy breast cancer tumors.

We believe that Bria-IMT™

induces an antitumor response both indirectly (i.e., by providing the tumor antigens for the immune system to recognize) and directly by stimulating the immune system (i.e., further activating T-cells), which collectively boosts the body’s response.

Learn More
Off-The-Shelf Personalized Immunotherapy

Bria-OTS™

Supported by the data, “Matching Hypothesis” resulted in BriaCell’s “OTS” strategy.

Introducing Bria-OTS™

  • We believe our treatment is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type.
  • We are engineering 15 unique HLA types (molecules), collectively referred to as Bria-OTS™, allowing for what we believe will be matching and treatment of over 99% of patients with advanced breast cancer.
  • Bria-OTS™ involves a simple saliva test to determine the HLA-type of each patient.
  • Each patient will then be treated with the appropriate pre-manufactured Bria-OTS™ formulation.
  • Similar cell lines in development for prostate cancer, lung cancer, and melanoma.
  • Preclinical models for the Bria-OTS™ technology are in development under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) in the U.S.
Learn More
briacell logo

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW;TSXV: BCT) is a clinical stage immunotherapy company developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors.

  • Our lead drug candidate is Bria-IMT™. Our clinical program targets third-line advanced breast cancer, which causes over 40,000 deaths per year in the U.S. alone.
    • 35 patients have been dosed to-date and showed robust responses in predictable sub-groups of patients → Our Phase I/IIa safety & efficacy show similar or superior results to those of other advanced or approved drugs for breast cancer when they were at similar stages of clinical development.
  • Incyte Corporation (Nasdaq: INCY) → BriaCell has established a corporate collaboration and supply agreement with Incyte.
    • This is a non-exclusive clinical trial collaboration to evaluate the effects of combination therapies.

Bria-IMT™ + immune checkpoint inhibitors (Phase I/IIa)

  1. Bria-IMT™ + pembrolizumab (KEYTRUDA® from Merck) was initially evaluated in 11 patients → this study then transitioned to combinations with Incyte’s immune checkpoint inhibitors.
  2. Bria-IMT™ + Incyte’s selected compounds are being investigated under the corporate collaboration and supply agreement.
  • BriaCell is driving toward a Registration Study, with initiation of the study expected in 2022 → Bria-IMT™ combined with immune checkpoint inhibitor(s).
  • Bria-OTS™: BriaCell is developing an “Off-The-Shelf Personalized” immunotherapy based on a patient’s HLA-type.
    • HLA molecules start immune responses but vary in the population.
    • BriaCell’s preliminary data suggests that patients who match Bria-IMT™ at one or more HLA “types” are more likely to have clinical benefit.
    • This has led to the development of Bria-OTS™, where the cells have been genetically engineered to match the HLA type of the broader patient population.
    • BriaCell is extending this technology to other types of cancer (prostate cancer, lung cancer, and melanoma).
    • This technology is being evaluated in a Collaborative Research and Development Agreement with the National Cancer Institute (part of NIH).
  • CEO Dr. William Williams has been involved in 11 prior drug approvals.